Clinical Trial Update: Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of ARQ 621 in adults with metastatic solid tumors and refractory/relapsed hematologic malignancies has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Solid Tumors

Drugs mentioned

• ARQ 621

Snippet

Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Conditions: Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies | Phase 1 | Status: COMPLETED